IFI35 Polyclonal Antibody
Purified Rabbit Polyclonal Antibody (Pab)
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND

Application
| IHC-P, IHC-F, IF, E |
|---|---|
| Primary Accession | P80217 |
| Reactivity | Rat, Pig, Dog, Bovine |
| Host | Rabbit |
| Clonality | Polyclonal |
| Calculated MW | 31 KDa |
| Physical State | Liquid |
| Immunogen | KLH conjugated synthetic peptide derived from human IFI35 |
| Epitope Specificity | 101-200/286 |
| Isotype | IgG |
| Purity | affinity purified by Protein A |
| Buffer | 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| SUBCELLULAR LOCATION | Nucleus. Nuclear following IFN treatment. |
| SIMILARITY | Belongs to the NMI family. |
| SUBUNIT | Homodimer. Also interacts with B-ATF. |
| Important Note | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| Background Descriptions | The Interferon family of proteins are able to alter the expression of a variety of target genes, thereby controlling various events within the cell. IFI-35 (Interferon-induced 35 kDa protein), also known as IFP35, is a 286 amino acid interferon-induced protein. Localized to the nucleus and expressed in macrophages, fibroblasts and epithelial cells, IFI-35 is a leucine zipper protein that can form homodimers, but, unlike most leucine zipper proteins, cannot bind DNA. Upon induction by IFN-? IFI-35 associates with Nmi (N-Myc-interacting protein), resulting in the formation of a high molecular weight complex that is thought to play a role in IFN-?signaling and cellular responses. Once complexed with Nmi, IFI-35 is unable to be degraded by the proteasome, suggesting that IFI-35 is protected from degradation only when needed by IFN-? Two isoforms of IFI-35 exist due to alternative splicing events. |
| Gene ID | 3430 |
|---|---|
| Other Names | Interferon-induced 35 kDa protein, IFP 35, Ifi-35, IFI35 (HGNC:5399) |
| Target/Specificity | In a wide range of cell types, including fibroblasts, macrophages, and epithelial cells. |
| Dilution | IHC-P=1:100-500,IHC-F=1:100-500,IF=1:50-200,ELISA=1:5000-10000 |
| Storage | Store at -20 ℃ for one year. Avoid repeated freeze/thaw cycles. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 ℃. |
| Name | IFI35 (HGNC:5399) |
|---|---|
| Function | Acts as a signaling pathway regulator involved in innate immune system response (PubMed:26342464, PubMed:29038465, PubMed:29350881). In response to interferon IFN-alpha, associates in a complex with signaling pathway regulator NMI to regulate immune response; the complex formation prevents proteasome-mediated degradation of IFI35 and correlates with IFI35 dephosphorylation (PubMed:10779520, PubMed:10950963). In complex with NMI, inhibits virus-triggered type I interferon/IFN-beta production (PubMed:26342464). In complex with NMI, negatively regulates nuclear factor NF-kappa-B signaling by inhibiting the nuclear translocation, activation and transcription of the NF-kappa-B subunit p65/RELA, resulting in the inhibition of endothelial cell proliferation, migration and re-endothelialization of injured arteries (PubMed:29350881). Beside its role as an intracellular signaling pathway regulator, also functions extracellularly as damage-associated molecular patterns (DAMPs) to promote inflammation when actively released by macrophage to the extracellular space during cell injury and pathogen invasion (PubMed:29038465). Macrophage-secreted IFI35 activates NF-kappa-B signaling in adjacent macrophages through Toll- like receptor 4/TLR4 activation, thereby inducing NF-kappa-B translocation from the cytoplasm into the nucleus which promotes the release of pro-inflammatory cytokines (PubMed:29038465). |
| Cellular Location | Cytoplasm. Nucleus. Secreted Note=Cytoplasmic IFI35 localizes in punctate granular structures (PubMed:10950963). Nuclear localization increased is stimulated by IFN- alpha (PubMed:10950963, PubMed:8288566). Extracelullar following secretion by macrophage (PubMed:29038465) |
| Tissue Location | Expressed in a wide range of cell types, including fibroblasts, macrophages, and epithelial cells |

Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.





Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.

